Drug Trial News

RSS
EMA grants PRIME designation to Themis' chikungunya vaccine candidate

EMA grants PRIME designation to Themis' chikungunya vaccine candidate

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Esophageal cancer risk could be reduced by esomeprazole and low dose aspirin

Esophageal cancer risk could be reduced by esomeprazole and low dose aspirin

MiNA Therapeutics announces initial results from phase I trial of saRNA candidate in liver cancer patients

MiNA Therapeutics announces initial results from phase I trial of saRNA candidate in liver cancer patients

Protein inhibitor drug found to be safe and effective in treating patients with acute myeloid leukemia

Protein inhibitor drug found to be safe and effective in treating patients with acute myeloid leukemia

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

New trial to test if omega-3 capsules can stop secondary liver cancer recurrence after surgery

New trial to test if omega-3 capsules can stop secondary liver cancer recurrence after surgery

Fewer women meet eligibility criteria for clinical trial of heart failure drugs, study finds

Fewer women meet eligibility criteria for clinical trial of heart failure drugs, study finds

Researchers find novel ways to improve participation in clinical research

Researchers find novel ways to improve participation in clinical research

Bath geriatrician leads new UK-wide trial into Parkinson’s disease

Bath geriatrician leads new UK-wide trial into Parkinson’s disease

Antioxidant-enriched multivitamin may decrease respiratory illnesses in CF patients, finds study

Antioxidant-enriched multivitamin may decrease respiratory illnesses in CF patients, finds study

NIH commences first-in-human trial evaluating experimental treatment for Ebola

NIH commences first-in-human trial evaluating experimental treatment for Ebola

PanOptica doses first patient in Phase 1/2 dose-ranging clinical trial of PAN-90806

PanOptica doses first patient in Phase 1/2 dose-ranging clinical trial of PAN-90806

Investigational drug offers hope of relief for celiac disease patients exposed to gluten

Investigational drug offers hope of relief for celiac disease patients exposed to gluten

Researchers to test two-pronged approach in humans to treat advanced colorectal cancer

Researchers to test two-pronged approach in humans to treat advanced colorectal cancer

Pfizer starts Phase 1/2 study of RSV vaccine candidate in healthy adult volunteers

Pfizer starts Phase 1/2 study of RSV vaccine candidate in healthy adult volunteers

Clinical trial begins enrollment to test safety of experimental MERS treatments

Clinical trial begins enrollment to test safety of experimental MERS treatments

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts

Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.